Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAMK1D | Q8IU85 | 20/20 | 0.61 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.60 |
| ▸ | CSF1R | P07333 | 1/20 | 0.60 |
| ▸ | PIM1 | P11309 | 1/20 | 0.60 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | SYK | P43405 | 1/20 | 0.60 |
| ▸ | BLK | P51451 | 1/20 | 0.60 |
| ▸ | RIPK4 | P57078 | 1/20 | 0.60 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.60 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.60 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.60 |
| ▸ | MAP3K11 | Q16584 | 1/20 | 0.60 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28509414 | 0.87 | CAMK1D (0.81) | CAMK1DMAP3K7CSF1RPIM1MAPK3 | |
| SCHEMBL28500208 | 0.85 | CAMK1D (0.69) | CAMK1DMAP3K7CSF1RPIM1MAPK3 | |
| SCHEMBL28500211 | 0.85 | CAMK1D (0.69) | CAMK1DMAP3K7CSF1RPIM1MAPK3 | |
| SCHEMBL23113585 | 0.84 | CAMK1D (0.64) | CAMK1DMAP3K7CSF1RPIM1MAPK3 | |
| SCHEMBL28501286 | 0.83 | CAMK1D (0.81) | CAMK1DMAP3K7CSF1RPIM1MAPK3 | |
| SCHEMBL28501285 | 0.83 | CAMK1D (0.81) | CAMK1DMAP3K7CSF1RPIM1MAPK3 | |
| SCHEMBL28499382 | 0.82 | CAMK1D (0.81) | CAMK1D | |
| SCHEMBL28501134 | 0.82 | CAMK1D (0.77) | CAMK1DKCNH2MAP2K5MAP3K11 | |
| SCHEMBL28501131 | 0.82 | CAMK1D (0.77) | CAMK1DKCNH2MAP2K5MAP3K11 | |
| SCHEMBL28496491 | 0.82 | CAMK1D (0.77) | CAMK1DRIPK4KCNH2MAP2K5MAP3K11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11530193-B2 | Kinase inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2022-12-20 | — | — | US | disclosed |
| EP-3793996-A1 | KINASE INHIBITORS | The University of Manchester (GB) | 2021-03-24 | — | — | EP | disclosed |
| CN-112119077-A | Kinase inhibitors | 曼彻斯特大学 | 2020-12-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11530193-B2 | Kinase inhibitors | CAMKK2, CAMK1, CAMKK1 | CAMK1D 5/4885MAP3K7 33/4885CSF1R 1888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.